氧化合成酶抑制防止细胞在质母细胞瘤中的增殖
Daniel Kruglyakov1, Shashank Kumar Ojha1, Maryam Kartawy1
1Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
Journal of molecular neuroscience : MN
|October 16, 2023
概括
向氧化 (NO) 和其产生的酶,氧化合成酶 (NOS),用抑制剂L-NIL和7-NI,降低了GBM细胞的增殖. 这表明NO和NOS是质母细胞瘤多种类型 (GBM) 的潜在治疗点.
科学领域:
- 神经科学是一个神经科学.
- 在瘤学瘤学.
- 生物化学 生物化学
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有高复发率的侵袭性脑瘤.
- 在GBM中观察到高氧化 (NO) 水平和失调的氧化合成酶 (NOS) 活性,特别是可诱导的NOS (iNOS) 和神经元NOS (nNOS).
- 是一种关键的信号分子,与细胞增殖和神经元功能有关.
研究的目的:
- 研究在GBM中抑制iNOS和nNOS的治疗潜力.
- 为了测试药理干预iNOS和nNOS抑制剂可以阻碍GBM进展的假设.
主要方法:
- 利用U87-MG细胞系作为GBM的体外模型.
- 服用N6-(1-iminoethyl) -L-lysine (L-NIL),一种iNOS抑制剂,以及7-Nitroindazole (7-NI),一种nNOS抑制剂.
- 评估了L-NIL和7-NI对NO度,NOS活性和细胞增殖的影响.
主要成果:
- 用L-NIL和7-NI治疗显著降低了U87-MG细胞中的NO度.
- 抑制剂治疗导致GBM细胞模型中的NOS活性下降.
- L-NIL和7-NI表明,U87-MG细胞的克隆性增殖减少了.
结论:
- NO和NOS酶代表了多种质母细胞瘤的有前途的治疗点.
- 针对性抑制iNOS和nNOS可能为GBM治疗提供一种新的策略.
- 对GBM的NO调节疗法进行进一步的研究是有必要的.
更多相关视频
08:32Application of Genetically Encoded Fluorescent Nitric Oxide (NO•) Probes, the geNOps, for Real-time Imaging of NO• Signals in Single Cells
Published on: March 16, 2017
12.9K
09:26Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
16.7K
相关概念视频
Nitric Oxide Signaling Pathway
5.0K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.0K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
